According to filings with the U.S. Securities and Exchange Commission, Darmiyan is raising $3,536,249.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Padideh Kamali-Zare played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Darmiyan
Novel quantitative virtual microscopy for early detection of Alzheimers disease from non-invasive MRI. Our Vision: Precision Brain Health Screening & Monitoring for All – using our novel cutting-edge neuroscience-powered AI & brain imaging software. Our Brand: Darmiyan is a Persian word that means in-between. Our technology focuses on the space in between brain cells. We grade the health of that space so that people begin to understand what’s happening in between normal health and neurodegenerative disease. We are a team of neuroscientists, data scientists, visionary healthcare experts and business people focused on impacting the lives of millions of people around the world who suffer from brain diseases. We decode the mysterious world of the brain through high-standard, neuroscience-powered AI methods to measure and monitor changes that happen in our brain tissue architecture in response to our environment, food, activities, mindset, and medications. Such powerful tools that give insights into our individual brains are currently missing. Darmiyan team and technology strive to open a new window into the human brain. We intend to improve the entire brain health paradigm for patients, healthcare providers, pharmaceutical companies and others advancing health and wellness.

To learn more about Darmiyan, visit http://www.darmiyan.com/

Contact:
Padideh Kamali-Zare, Chief Executive Officer
917-689-0389

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.